Inherited WNT9B mutation linked to increased prostate cancer risk, study finds

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.

April 11, 2025

Vol.51 No.14

Drugs & Targets

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

Clinical Roundup

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

A new large-scale study, co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators, provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is equally as effective as conventional radiotherapy for prostate cancer, without compromising patient safety.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

A five-year study on subjects who had only the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Immunotherapy may have potential as prostate cancer treatment, study shows

A study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a synergistic treatment approach.

March 07, 2025

Vol.51 No.09

Inherited WNT9B mutation linked to increased prostate cancer risk, study finds

YOU MAY BE INTERESTED IN

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

FDA approves prostate cancer imaging agent Gozellix

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

Immunotherapy may have potential as prostate cancer treatment, study shows

Renew today!

Subscriber content

Never miss an issue!

Login